NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS
申请人:MEDIBIOFARMA, S.L.
公开号:EP3498694A1
公开(公告)日:2019-06-19
The present invention relates to novel benzamides derivatives of formula (I)
as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.
[EN] PPARG INVERSE AGONISTS AND USES THEREOF<br/>[FR] AGONISTES INVERSES DE PPARG ET LEURS UTILISATIONS
申请人:FLARE THERAPEUTICS INC
公开号:WO2022187203A1
公开(公告)日:2022-09-09
Provided are compounds of Formula (I): (I); and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
[EN] NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS<br/>[FR] NOUVEAUX DÉRIVÉS BENZAMIDES UTILISÉS EN TANT QUE MODULATEURS DE PPAR-GAMMA
申请人:MEDIBIOFARMA S L
公开号:WO2019115498A1
公开(公告)日:2019-06-20
The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.
Nonsteroidal antiinflammatory agents. III. Synthesis of the metabolites of 10,11-dihydro-8,.ALPHA.-dimethyl-11-oxodibenz(b,f)oxepin-2-acetic acid (bermoprofen).
作者:KATSUHIKO HINO、HIDEO NAKAMURA、SHIRO KATO、AKIRA IRIE、YASUTAKA NAGAI、HITOSHI UNO
DOI:10.1248/cpb.36.3462
日期:——
The metabolites (3 and 4) of 10, 11-dihydro-8, α-dimethyl-11-oxodibenz[b, f]oxepin-2-acetic acid (bermoprofen, AD-1590, 1), a promising antiinflammatory drug, were synthesized to confirm the proposed structures, and all the metabolites (2-4) were tested for activity in the carrageenin-induced edema test in rats. Metabolites 2 and 3 showed slight inhibition but 4 had no effect after intravenous administration.